Gust Verleni, PA
Medical · Jamestown, NYNPI 1811988801
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 762 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,777, 3.4 times the $1,111 reported in 2021. Among medical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 762 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$776
- Neurocrine Biosciences, Inc.$735
- plus $4K from 18 others
What the payments were for
- Food & beverage$12,52999%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 106 | $2,096 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 162 | $2,083 |
| Otsuka America Pharmaceutical, Inc. | 81 | $1,453 |
| Alkermes, Inc. | 72 | $1,282 |
| Teva Pharmaceuticals USA, Inc. | 51 | $776 |
| Neurocrine Biosciences, Inc. | 38 | $735 |
| Vanda Pharmaceuticals Inc. | 26 | $575 |
| Lundbeck LLC | 48 | $567 |
| Supernus Pharmaceuticals, Inc. | 30 | $559 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $496 |
| Axsome Therapeutics, Inc. | 18 | $469 |
| E.r. Squibb & Sons, L.L.C. | 14 | $402 |
| Corium, LLC | 13 | $271 |
| Indivior Inc. | 20 | $192 |
| Ironshore Pharmaceuticals Inc. | 7 | $151 |
| Sunovion Pharmaceuticals Inc. | 15 | $146 |
| Johnson & Johnson | 6 | $106 |
| Acadia Pharmaceuticals Inc | 4 | $68 |
| Idorsia Pharmaceuticals US Inc | 3 | $56 |
| Almatica Pharma LLC | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $40 |
| Gilead | 1 | $26 |
| Eisai Inc. | 1 | $24 |
| Alfasigma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,628 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $104,287 |
| VraylarCariprazine Hcl | 52 | $71,947 |
| RexultiBrexpiprazole | 48 | $71,946 |
| Risperdal ConstaRisperidone Microspheres | 48 | $69,015 |
| Abilify MaintenaAripiprazole | 19 | $55,680 |
| Invega SustennaPaliperidone Palmitate | 15 | $47,924 |
| AristadaAripiprazole Lauroxil | 15 | $44,909 |
| TrintellixVortioxetine Hydrobromide | 63 | $36,869 |
| CaplytaLumateperone Tosylate | 15 | $26,374 |
| Lurasidone Hcl | 92 | $25,880 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 113 | $20,539 |
| Aripiprazole | 369 | $13,868 |
| BelsomraSuvorexant | 25 | $10,417 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 389 | $3,739 |
| Bupropion XlBupropion Hcl | 229 | $3,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,453 | $127,62667 claims |
| Johnson & JohnsonRisperdal Consta, Invega Sustenna | $106 | $116,93963 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $735 | $104,28713 claims |
| AbbVieVraylar | $2,096 | $71,94752 claims |
| Alkermes, Inc.Aristada | $1,282 | $44,90915 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $496 | $36,86963 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,083 | $26,37415 claims |
| Almatica Pharma LLCSertraline Hcl | $41 | $1,137237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.
Other medical in Jamestown
- Connie ScarpineJamestown$16K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.